NovaBridge Biosciences
NASDAQ · us_market
No AI insight generated yet for this ticker.
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 1.39M | $3.42M | 0.00% | Trimmed-39.6% | 2026-03-31 |
| StateStreet | passive | 370.1K | $910.46K | 0.00% | Added+2.8% | 2026-03-31 |
| RenTech | quant | 272.4K | $670.13K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-01upcoming | -0.23 | — | — |
| 2026-04-07 | -0.08 | -0.31 | -287.50% |
| 2025-12-18 | -0.05 | -0.06 | -20.00% |
| 2025-08-20 | -0.12 | -0.07 | +41.67% |
| 2025-05-15 | -0.07 | -0.04 | +42.86% |
| 2025-04-03 | -0.05 | -0.06 | -20.00% |
| 2024-11-14 | -0.07 | -0.11 | -57.14% |
| 2024-08-28 | -0.22 | 0.30 | +233.93% |
| 2022-11-09 | -0.36 | -0.60 | -64.34% |
| 2022-04-28 | -0.51 | -0.70 | -37.70% |
| 2021-11-11 | -0.51 | -0.86 | -69.05% |
| 2021-04-28 | 0.71 | 0.56 | -21.20% |
| 2020-08-31 | -0.53 | -0.80 | -51.53% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NBP | -22.69% | -42.50% | -53.77% | +40.46% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -25.66% | -37.86% | -50.33% | +27.77% |